 AIM ImmunoTech Inc has announced a new provisional patent application for its flagship drug candidate Ampligen as both an intranasal and an intravenous therapy for what the company describes as Post-COVID-19 Cognitive Dysfunction PCCD. The Ocala, Florida-based immuno-pharma company has been working steadily to expand its coronavirus COVID-19 patent portfolio. 